BACKGROUND: Although transplantation of genetically modified porcine livers into baboons has yielded recipient survival for up to 7 days, survival is limited by profound thrombocytopenia, which becomes manifest almost immediately after revascularization, and by subsequent coagulopathy. Porcine von Willebrand's factor (VWF), a glycoprotein that adheres to activated platelets to initiate thrombus formation, has been shown to constitutively activate human platelets via their glycoprotein Ib (GPIb) receptors. Here, we report our pig-to-primate liver xenoperfusion model and evaluate whether targeting the GPIb-VWF axis prevents platelet sequestration. METHODS: Twelve baboons underwent cross-circulation with the following extracorporeal livers: one allogeneic control with a baboon liver, 4 xenogeneic controls with a GalTKO.hCD46 pig liver, 3 GalTKO.hCD46 pig livers in recipients treated with αGPIb antibody during perfusion, and 4 GalTKO.hCD46 pig livers pre-treated with D-arginine vasopressin (DDAVP) in recipients treated with αGPIb antibody during perfusion. RESULTS: All perfused livers appeared grossly and macroscopically normal and produced bile. Xenograft liver perfusion experiments treated with αGPIb antibody may show less platelet sequestration during the initial 2 h of perfusion. Portal venous resistance remained constant in all perfusion experiments. Platelet activation studies demonstrated platelet activation in all xenoperfusions, but not in the allogeneic perfusion. CONCLUSION: These observations suggest that primate platelet sequestration by porcine liver and the associated thrombocytopenia are multifactorial and perhaps partially mediated by a constitutive interaction between porcine VWF and the primate GPIb receptor. Control of platelet sequestration and consumptive coagulopathy in liver xenotransplantation will likely require a multifaceted approach in our clinically relevant perfusion model.
BACKGROUND: Although transplantation of genetically modified porcine livers into baboons has yielded recipient survival for up to 7 days, survival is limited by profound thrombocytopenia, which becomes manifest almost immediately after revascularization, and by subsequent coagulopathy. Porcine von Willebrand's factor (VWF), a glycoprotein that adheres to activated platelets to initiate thrombus formation, has been shown to constitutively activate human platelets via their glycoprotein Ib (GPIb) receptors. Here, we report our pig-to-primate liver xenoperfusion model and evaluate whether targeting the GPIb-VWF axis prevents platelet sequestration. METHODS: Twelve baboons underwent cross-circulation with the following extracorporeal livers: one allogeneic control with a baboon liver, 4 xenogeneic controls with a GalTKO.hCD46pig liver, 3 GalTKO.hCD46pig livers in recipients treated with αGPIb antibody during perfusion, and 4 GalTKO.hCD46pig livers pre-treated with D-arginine vasopressin (DDAVP) in recipients treated with αGPIb antibody during perfusion. RESULTS: All perfused livers appeared grossly and macroscopically normal and produced bile. Xenograft liver perfusion experiments treated with αGPIb antibody may show less platelet sequestration during the initial 2 h of perfusion. Portal venous resistance remained constant in all perfusion experiments. Platelet activation studies demonstrated platelet activation in all xenoperfusions, but not in the allogeneic perfusion. CONCLUSION: These observations suggest that primate platelet sequestration by porcine liver and the associated thrombocytopenia are multifactorial and perhaps partially mediated by a constitutive interaction between porcine VWF and the primate GPIb receptor. Control of platelet sequestration and consumptive coagulopathy in liver xenotransplantation will likely require a multifaceted approach in our clinically relevant perfusion model.
Authors: Scott L Nyberg; Toshikazu Yagi; Takakazu Matsushita; Joseph Hardin; Joseph P Grande; Lawrence E Gibson; Jeffrey L Platt Journal: Liver Transpl Date: 2003-03 Impact factor: 5.799
Authors: J B Siegel; S T Grey; B A Lesnikoski; C W Kopp; M Soares; J Schulte am Esch; F H Bach; S C Robson Journal: Transplantation Date: 1997-09-27 Impact factor: 4.939
Authors: H Terajima; Y Shirakata; T Yagi; S Mashima; H Shinohara; S Satoh; Y Arima; T Gomi; T Hirose; R Takahashi; I Ikai; T Morimoto; T Inamoto; M Yamamoto; Y Yamaoka Journal: Transplantation Date: 1997-02-27 Impact factor: 4.939
Authors: R Nishitai; I Ikai; H Terajima; A Kanazawa; O Takeyama; T Uesugi; H Okabe; N Katsura; T Matsushita; S Yamanokuchi; K Matsuo; S Sugimoto; T Shiotani; Y Yamaoka Journal: Liver Transpl Date: 2001-07 Impact factor: 5.799
Authors: R S Chari; B H Collins; J C Magee; J M DiMaio; A D Kirk; R C Harland; R L McCann; J L Platt; W C Meyers Journal: N Engl J Med Date: 1994-07-28 Impact factor: 91.245
Authors: C W Kopp; J B Siegel; W W Hancock; J Anrather; H Winkler; C L Geczy; E Kaczmarek; F H Bach; S C Robson Journal: Transplantation Date: 1997-03-15 Impact factor: 4.939
Authors: I M Sauer; D Kardassis; K Zeillinger; A Pascher; A Gruenwald; G Pless; M Irgang; M Kraemer; G Puhl; J Frank; A R Müller; T Steinmüller; J Denner; P Neuhaus; J C Gerlach Journal: Xenotransplantation Date: 2003-09 Impact factor: 3.907
Authors: Takakazu Matsushita; Bruce Amiot; Joseph Hardin; Jeffrey L Platt; Scott L Nyberg Journal: Transplantation Date: 2003-11-15 Impact factor: 4.939
Authors: Arielle Cimeno; Wessam Hassanein; Beth M French; Jessica M Powell; Lars Burdorf; Olga Goloubeva; Xiangfei Cheng; Dawn M Parsell; Jagdeece Ramsoondar; Kasinath Kuravi; Todd Vaught; Mehmet C Uluer; Emily Redding; Natalie O'Neill; Christopher Laird; Alena Hershfeld; Ivan Tatarov; Kathryn Thomas; David Ayares; Agnes M Azimzadeh; Richard N Pierson; Rolf N Barth; John C LaMattina Journal: Xenotransplantation Date: 2017-09-22 Impact factor: 3.907
Authors: L Burdorf; A Riner; R N Pierson; A M Azimzadeh; E Rybak; I I Salles; S F De Meyer; A Shah; K J Quinn; D Harris; T Zhang; D Parsell; F Ali; E Schwartz; E Kang; X Cheng; E Sievert; Y Zhao; G Braileanu; C J Phelps; D L Ayares; H Deckmyn; Amy Dandro; Kasinath Karavi Journal: Xenotransplantation Date: 2016-05-18 Impact factor: 3.907